Related Experiment Video

Updated: Jul 6, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A molecular view of anti-ErbB monoclonal antibody therapy

Daniel J Leahy1

  • 1Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. dleahy@jhmi.edu

Cancer Cell
|April 9, 2008
PubMed

Insights

Matuzumab, an antibody targeting epidermal growth factor receptor (EGFR), binds and inhibits EGFR uniquely. This distinct mechanism suggests potential benefits when Matuzumab is used in combination with other cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Structural Biology

Background:

  • Aberrant signaling of epidermal growth factor receptor (EGFR) and HER2 is implicated in numerous human cancers.
  • Monoclonal antibodies targeting EGFR and HER2 are established anticancer treatments.
  • Structural insights into receptor-antibody interactions are crucial for understanding therapeutic mechanisms.

Purpose of the Study:

  • To investigate the structural and functional characteristics of the anti-EGFR monoclonal antibody Matuzumab.
  • To elucidate the binding and inhibitory mechanism of Matuzumab on EGFR.
  • To explore the potential of Matuzumab in combination cancer therapies.

Main Methods:

  • X-ray crystallography to determine the structure of Matuzumab bound to EGFR.
  • Biochemical assays to assess EGFR inhibition by Matuzumab.
  • Functional assays to evaluate the impact of Matuzumab on cancer cell proliferation.

Main Results:

  • Matuzumab exhibits a unique binding mode to the epidermal growth factor receptor (EGFR).
  • The antibody effectively inhibits EGFR signaling through a distinct mechanism compared to other anti-EGFR antibodies.
  • Structural data provides a basis for understanding Matuzumab's distinct inhibitory activity.

Conclusions:

  • Matuzumab represents a novel therapeutic antibody targeting EGFR with a unique mechanism of action.
  • The distinctive binding and inhibition profile of Matuzumab supports its potential use in combination therapies.
  • Further research into combination strategies involving Matuzumab may enhance anticancer efficacy.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...